AKT1 and hepatocellular carcinoma: In another in vivo HCC study, a CRISPR/Cas9 system was deployed for gene–chemo-combination therapy that used a silica nanoparticle to initiate CRISPR/Cas9 editing of EGFR, as well as the co-delivery of sorafenib to modulate EGFR-p13K-Akt expression and repress angiogenesis (61).